Boston Scientific Co. (NYSE:BSX) Shares Sold by Advisory Services Network LLC

Advisory Services Network LLC trimmed its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,134 shares of the medical equipment provider's stock after selling 3,616 shares during the quarter. Advisory Services Network LLC's holdings in Boston Scientific were worth $4,121,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BSX. TFC Financial Management Inc. lifted its holdings in Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares in the last quarter. Global Wealth Strategies & Associates raised its position in shares of Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 250 shares during the last quarter. West Oak Capital LLC purchased a new position in shares of Boston Scientific during the fourth quarter valued at approximately $29,000. Valley National Advisers Inc. boosted its position in Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 286 shares during the last quarter. Finally, Fairway Wealth LLC purchased a new stake in Boston Scientific in the 4th quarter worth approximately $36,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 0.2 %

Shares of Boston Scientific stock traded down $0.19 during trading hours on Tuesday, hitting $94.08. 2,216,926 shares of the company's stock traded hands, compared to its average volume of 6,347,166. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17. The company has a market cap of $139.15 billion, a PE ratio of 75.26, a PEG ratio of 2.79 and a beta of 0.73. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a 50 day simple moving average of $100.32 and a 200-day simple moving average of $94.18.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on BSX shares. Truist Financial reduced their price target on Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a research note on Friday. Wells Fargo & Company raised their price target on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Friday, January 10th. Morgan Stanley boosted their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, Argus set a $130.00 price target on shares of Boston Scientific in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $109.04.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 6,528 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $104.97, for a total transaction of $685,244.16. Following the completion of the sale, the executive vice president now owns 26,449 shares of the company's stock, valued at $2,776,351.53. This represents a 19.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.